BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q4 2023 vs. Q3 2023
How the institutions holding BIO-TECHNE Corp changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 530 | 9 | 532 | +11 |
| Shares | 152.2M | 37.9K | 155.5M | +3.30M (+2.2%) |
| Value | $10.4B | $2.58M | $12.0B | +$1.64B (+15.8%) |
9 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (82)
Institutions that held BIO-TECHNE Corp at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (71)
Institutions that held BIO-TECHNE Corp at the end of Q3 2023 and filed for Q4 2023 without it.
Not filed for Q4 2023 yet (9)
Institutions that held BIO-TECHNE Corp at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Pathstone Family Office, LLC | 10,936 | $744.4K |
| Icon Wealth Partners, LLC | 7,392 | $503.2K |
| First Republic Investment Management, Inc. | 5,997 | $408.2K |
| Focus Financial Network, Inc. | 5,692 | $387.5K |
| Advisor Partners II, LLC | 3,566 | $242.7K |
| Bryn Mawr Trust Co | 3,555 | $242.0K |
| Column Capital Advisors, LLC | 728 | $49.6K |
| Sutton Wealth Advisors Inc. | 43 | $2.93K |
| Steward Financial Group LLC | 33 | $2.00K |